Evidence map›Paper›PMID 42878873›Full record

SynthesisCell and tissue research2026

Artificial intelligence for stromal cell quality assessment: A systematic review of human mesenchymal stromal cell properties and viability.

William Li, Himal Kandel, Stephanie Baker, J Guy Lyons, Mojdeh Abbasi, Shrushti Surya, Athanasia Vardakis, Yuri Gervasiev, Stephanie Watson

Abstract readSystematic ReviewReview
PubMed Publisher
In one paragraph

Synthesis in Cell and tissue research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William LiSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. wili0140@uni.sydney.edu.au.
Himal KandelSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Stephanie BakerCollege of Science and Engineering, Faculty of Engineering, James Cook University, Cairns, Queensland, Australia.
J Guy LyonsCentenary Institute, The University of Sydney, Missenden Rd, Camperdown, New South Wales, 2050, Australia.
Mojdeh AbbasiSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Shrushti SuryaSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Athanasia VardakisSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Yuri GervasievSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Stephanie WatsonSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reliable assessment of mesenchymal stromal cell (MSC) viability and stem cell-associated properties is essential for ensuring the consistency, safety, and therapeutic potential of MSC cultures before clinical use. However, incomplete understanding of the mechanisms underlying MSC therapeutic effects remains a major barrier to clinical translation and to establishing reliable, standardised quality attributes. Artificial intelligence (AI) may enable automated assessment of these properties, but the performance and clinical relevance of AI-based approaches have not been systematically evaluated. This systematic review evaluated the accuracy and clinical utility of AI for assessing viability and stem cell-associated properties in human MSC cultures. Following PRISMA guidelines, we searched five electronic databases (Cochrane, Scopus, PubMed, EMBASE, and MEDLINE) for eligible studies reporting quantitative AI-based assessments of human MSC cultures. Two reviewers independently screened studies, extracted data, and assessed risk of bias using PROBAST. The review protocol was prospectively registered with PROSPERO (CRD420256393235). Of 3,872 records identified, 18 studies met the inclusion criteria. Supervised AI models, particularly convolutional neural networks, were most used. Across included studies, reported performance metrics varied substantially because of differences in AI models, imaging modalities, datasets, and outcome definitions. Considerable heterogeneity in AI model architectures, imaging modalities, outcome definitions, and reporting metrics limited direct comparison across studies. Overall, available evidence suggests that AI can assess key MSC quality attributes and may support more objective, scalable, and standardised quality-control workflows. However, broader validation, standardised reporting, external testing, and evaluation across a wider range of MSC characteristics are required before routine clinical implementation can be recommended.

Indexed as

Artificial IntelligenceMesenchymal Stem CellsCell SurvivalHumansArtificial intelligenceMesenchymal stromal cellsStemnessViability

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.